2011 was a challenging year for intellectual property (IP) in Brazil, with entrenched anti-IP local interests pitted against the establishment of a contemporary IP-based innovation society.
Important decisions were rendered by national courts on various subjects. In 2011 the first landmark decision recognising and enforcing data-package exclusivity protection for the pharmaceutical industry, limited to a 10-year term for new chemical entities, was made.
Additionally, the discussion about ANVISA’s (the Brazilian Food and Drug Administration) statutory authority to review patentability requirements reached a new, pro-inventor position.
Patents
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
Brazil, BPTO, ANVISA, Schering, Zynga, Germed